Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

WGS of clinical STI samples

ABSTRACT: Testing methods for WGS of STI bacteria from clinical samples

PROVIDER: PRJEB72167 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	ERR13397800.fastq.gz	Fastqsanger.gz
	ERR13385401.fastq.gz	Fastqsanger.gz
	ERR13397801.fastq.gz	Fastqsanger.gz
	ERR13397802.fastq.gz	Fastqsanger.gz
	ERR13397803.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 113

Similar Datasets

Ostrinia scapulalis WGS, 4 samples

Project description:Ostrinia scapulalis WGS, 4 samples

| PRJEB26557 | ENA

MGA-seq is an efficient tool for genetic variants and extrachromosomal DNA detection in cancer cell [WGS]

Project description:We developed MGA-seq for detecting both chromatin spatial contacts and WGS information at the same time in clinical samples, then we combine the two kind of information to detecte small variation, large structural variation, homogenously staining regions, and extrachromosomal DNA.

2023-09-14 | GSE205288 | GEO

Coliphages in Clinical Samples

Project description:Escherichia coli-Infecting Bacteriophages Isolated from Clinical Samples

| PRJEB32459 | ENA

WGS of Vibrio cholerae O1 El Tor strains

Project description:WGS of VC isolated from clinical samples

| PRJEB38941 | ENA

Clinical bronchoalveolar lavage (BAL) samples

Project description:Clinical bronchoalveolar lavage (BAL) samples Targeted loci

| PRJNA408304 | ENA

Clinical metagenomics analysis of wound swab samples.

Project description:Clinical metagenomics analysis of wound swab samples.

| PRJEB78614 | ENA

Shotgun metagenomics in clinical samples

Project description:Shotgun metagenomics for identification and typing of microorganisms in clinical samples

| PRJEB23830 | ENA

Pseudomonas aeruginosa mutators - clinical samples

Project description:Interspecific interactions infections select against Pseudomonas aeruginosa mutators, analysis of clinical samples

| PRJEB35620 | ENA

RNA Seq of P. aeruginosa clinical isolate collection

Project description:Purpose : The goal of this study was to use RNA Seq to explore the correlation of gene expression of a collection of clinical P. aeruginosa isolates to various phenotypes, such as antimicrobial resistance, biofilm formation or virulence Methods : mRNA profiles were generated for Pseudomonas aerugionsa clinical samples derived from various geographical locations by deep sequencing. The removal of ribosomal RNA was performed using the Ribo-Zero Bacteria Kit (Illumina) and cDNA libraries were generated with the ScriptSeq v2 Kit (Illumina) . The samples were sequenced in single end mode on an Illumina HiSeq 2500 device and mRNA reads were trimmed and mapped to the NC_008463.1 (PA14) reference genome from NCBI using Stampy pipeline with defaut settings.

2019-04-08 | GSE123544 | GEO

Reliable single cell array CGH for clinical samples

Project description:Establishment and subsequent validation of a aCGH protocol for WGA (whole genome amplification) products originating from single cell or low amount of starting material (i.e. microdissected FFPE tissue samples). The establishment of the protocol involved testing of three DNA labeling protocols. Two labeling protocols were designed specifically for Ampli1(TM) WGA products. Additionally random primed isothermal (Klenow-based) labeling approach was tested (Möhlendick et al., PLoS One. 2013 Jun 25;8(6):e67031.). In addition two different types of reference samples were tested and reference based on single-cell WGA products was chosen as most suitable in the end. The validation of the protocol assessed the following aspects: (1) performance of the protocol on primary and reamplified WGA products, (2) accuracy of the protocol in term of sensitivity of the CNA detection, (3) accuracy in terms of recapitulation of complex patterns of CNAs, (4) accuracy in terms of quantitative assessment of the CNAs, (5) ability to detect genomic heterogeneity of single cells (obtained either from in vitro cultures or from clinical patient material), (6) ability to detect minimal regions of aberration within a panel of disseminated cancer cells and corresponding tumor tissues.

2014-01-21 | GSE52366 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data